Ekso Bionics Holdings, Inc. (EKSO)
Market Cap | 19.45M |
Revenue (ttm) | 13.44M |
Net Income (ttm) | -14.77M |
Shares Out | 13.14M |
EPS (ttm) | -1.18 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 27,007 |
Open | 1.49 |
Previous Close | 1.54 |
Day's Range | 1.46 - 1.54 |
52-Week Range | 1.03 - 2.95 |
Beta | 1.76 |
Analysts | Buy |
Price Target | 9.18 (+520.27%) |
Earnings Date | Apr 26, 2023 |
About EKSO
Ekso Bionics Holdings, Inc. designs, develops, sells, and rents exoskeleton products in the Americas, Europe, the Middle east, Africa, the Asia Pacific, and internationally. The company operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods. It also provide... [Read more]
Financial Performance
In 2021, EKSO's revenue was $11.25 million, an increase of 26.62% compared to the previous year's $8.88 million. Losses were -$9.76 million, -38.30% less than in 2020.
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for EKSO stock is "Buy." The 12-month stock price forecast is $9.18, which is an increase of 520.27% from the latest price.
News

Ekso Bionics Reports Fourth Quarter and Year End 2022 Results
SAN RAFAEL, Calif., March 28, 2023 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today re...

Ekso Bionics to Showcase Integrated Functional Electrical Stimulation for Indego Therapy at APTA Meeting
SAN RAFAEL, Calif., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Ekso Bionics (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced it will ...

Ekso Bionics Announces Acquisition of Human Motion and Control Business Unit Including Indego® Product Line From Parker Hannifin Corporation
Broadens Ekso Bionics' product portfolio into home use

Ekso Bionics (EKSO) Reports Q3 Loss, Lags Revenue Estimates
Ekso Bionics (EKSO) delivered earnings and revenue surprises of -37.50% and 7.01%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Ekso Bionics Reports Third Quarter 2022 Results
Quarterly Record of 33 EksoNR Bookings in Q3 2022

Ekso Bionics to Present at H.C. Wainwright 24th Annual Global Investment Conference
SAN RAFAEL, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today an...

Ekso Bionics (EKSO) Reports Q2 Loss, Misses Revenue Estimates
Ekso Bionics (EKSO) delivered earnings and revenue surprises of 4.17% and 0.72%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Ekso Bionics Reports Second Quarter 2022 Results
RICHMOND, Calif., July 28, 2022 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today repor...

Ekso Bionics to Report Second Quarter 2022 Financial Results on July 28
RICHMOND, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today annou...

Ekso Bionics Receives FDA Clearance to Market its EksoNR™ Robotic Exoskeleton for Use with Multiple Sclerosis Patients
First FDA Cleared Exoskeleton for Rehabilitation Use in Patients with Multiple Sclerosis

Ekso Bionics Appoints Jerome Wong Interim Chief Financial Officer
RICHMOND, Calif., May 26, 2022 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announ...

Ekso Bionics (EKSO) Could Find Support Soon, Here's Why You Should Buy the Stock Now
Ekso Bionics (EKSO) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among W...

Ekso Bionics (EKSO) Reports Q1 Loss, Lags Revenue Estimates
Ekso Bionics (EKSO) delivered earnings and revenue surprises of 12.20% and 19.78%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Ekso Bionics Reports First Quarter 2022 Results
RICHMOND, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today repo...

Ekso Bionics to Report First Quarter 2022 Financial Results on April 28
RICHMOND, Calif., April 21, 2022 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today anno...

Ekso Bionics (EKSO) Reports Q4 Loss, Tops Revenue Estimates
Ekso Bionics (EKSO) delivered earnings and revenue surprises of 8% and 1.90%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Ekso Bionics to Report Fourth Quarter and Full Year 2021 Financial Results on February 24, 2022
RICHMOND, Calif., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today annou...

Ekso Bionics Announces Leadership Transition
Board Member Steven Sherman to be Appointed CEO

Ekso Bionics Reports Preliminary Fourth Quarter and Full Year 2021 Financial Results
Company Achieves Record Quarterly Revenue of $3.9 million to $4.1 million 1

Ekso Bionics to Participate at the H.C. Wainwright BioConnect Virtual Conference
RICHMOND, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO), an industry leader in exoskeleton technology for medical and industrial use, today announced that manage...

Ekso Bionics Appoints Corinna E. Lathan, Ph.D.
RICHMOND, Calif., Dec. 28, 2021 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today annou...

Ekso Bionics Announces EksoNR Multi-Unit Order by Nebraska Fraternal Order of Eagles
- Foundation Donates Units to Two Inpatient Rehabilitation Facilities in Nebraska -

Ekso Bionics (EKSO) Reports Q3 Loss, Tops Revenue Estimates
Ekso Bionics (EKSO) delivered earnings and revenue surprises of 32.00% and 18.18%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Ekso Bionics Reports Third Quarter 2021 Results
RICHMOND, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today repor...

Ekso Bionics to Report Third Quarter 2021 Financial Results on November 2, 2021
RICHMOND, Calif., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today annou...